Background: Mastocytosis is a disorder characterized by the accumulation of mast cells in various organs, most commonly in the skin. Cutaneous mastocytosis (CM) can be classified as nodular CM with solitary or multiple lesions, diffuse CM (erythroderma), and maculopapular CM including the papular/plaque variant, urticaria pigmentosa (UP) and telangiectasia macularis eruptiva perstans (TMEP). Objective: To evaluate the dermatoscopic features of cutaneous mastocytosis. Methods: We reviewed the dermatoscopic images of 6 patients who had different variants of cutaneous mastocytosis and who attended the Departments of Dermatology at the Medical University of Ankara, Turkey, and the Medical University of Vienna, Austria. Results: In UP and in the papular variant of CM the most common structures seen by dermatoscopy were brown reticular lines (pigment network). In TMEP we observed telangiectatic vessels arranged in a reticular pattern. Conclusion: Skin lesions of mastocytosis may exhibit a pigment network, a dermatoscopic feature said to be characteristic of melanocytic lesions. We were also able to identify a new dermatoscopic feature, a reticular vascular pattern that is characteristic of a clinical variant of mastocytosis known as TMEP. This feature may help to differentiate TMEP from other variants of mastocytosis and from other exanthematous skin diseases.

1.
Wolff K, Komar M, Petzelbauer P: Clinical and histopathological aspects of cutaneous mastocytosis. Leuk Res 2001;25:519–528.
2.
Funasaka Y, Boulton T, Cobb M, Yarden Y, Fan B, Lyman SD, Williams DE, Anderson DM, Zakut R, Mishima Y: C-Kit-kinase induces a cascade of protein tyrosine phosphorylation in normal human melanocytes in response to mast cell growth factor and stimulates mitogen-activated protein kinase but is down-regulated in melanomas. Mol Biol Cell 1992;3:197–209.
3.
Geissler EN, Ryan MA, Housman DE: The dominant-white spotting (W) locus of the mouse encodes the c-kit proto-oncogene. Cell 1988;55:185–192.
4.
Arpaia N, Cassano N, Vena GA: Lessons on dermoscopy: pigment network in nonmelanocytic lesions. Dermatol Surg 2004;30:929–930.
5.
Argenziano G, Soyer HP, Chimenti S, Talamini R, Corona R, Sera F, Binder M: Dermoscopy of pigmented skin lesions: results of a consensus meeting via the internet. J Am Acad Dermatol 2003;48:679–693.
6.
Yadav S, Vossaert KA, Kopf AW, Silverman M, Grin-Jorgensen C: Histopathologic correlates of structures seen on dermoscopy (epiluminescence microscopy). Am J Dermatopathol 1993;15:297–305.
7.
Argenziano G, Soyer HP, De Giorgi V, Piccolo D, Carli P, Delfino M, et al: Interactive Atlas of Dermoscopy. Milan, EDRA Medical Publishing & New Media 2000, pp 297–305 (CD-ROM).
8.
Arpaia N, Cassano N, Vena GA: Dermatofibroma: a case report and personal considerations. Dermatol Surg 2004;30:421.
9.
De Giorgi V, Massi D, Stante M, Carli P: False ‘melanocytic’ parameters shown by pigmented seborrheic keratoses: a finding which is not uncommon in dermoscopy. Dermatol Surg 2002;28:776–779.
10.
Halaban R, Tyrrell L, Longley J, Yarden Y, Rubin J: Pigmentation and proliferation of human melanocytes and the effects of melanocyte-stimulating hormone and ultraviolet B light. Ann NY Acad Sci 1993;680:290–301.
11.
Horny HP, Valent P: Histopathological and immunohistochemical aspects of mastocytosis. Int Arch Allergy Immunol 2002;127:115–117.
12.
Wimazal F, Jordan JH, Sperr WR, Chott A, Dabbass S, Klaus L, Horny HP, Valent P: Increased angiogenesis in the bone marrow of patients with systemic mastocytosis. Am J Pathol 2002;160:1639–1645.
13.
Palmer A, Bowling J: Dermoscopic appearance of juvenile xantogranuloma. Dermatology 2007;215:256–259.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.